A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Key facts

Sponsor

Ipsen

Principal Investigator

Ipsen Medical, Director

Ipsen

Enrollment

100 enrolled

Eligibility

8 years · All sexes

Timeline

2024 – 2035

Study locations (5)

• The Regents of the University of California, San Francisco, California, United States
• The Trustees of the University of Pennsylvania, Office of Clinical Research-Legal Services, Perelman School of Medicine, Philadelphia, Pennsylvania, United States
• Edmonton Clinic Health Academy (ECHA)- University of Alberta, Edmonton, Canada
• Bone Research and Education Centre, Oakville, Canada
• University Health Network (UHN) - Toronto General, Toronto, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Fibrodysplasia ossificans progressiva

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06724562
  IL1 Inhibition in FOP
  University of California, San Francisco
• ACTIVE NOT RECRUITINGPHASE2, PHASE3NCT06508021
  A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
  Ashibio Inc
• ACTIVE NOT RECRUITINGPHASE3NCT05394116
  A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)
  Regeneron Pharmaceuticals
• RECRUITINGPHASE2NCT05090891
  To Assess the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
  Incyte Corporation
• RECRUITINGNCT02745158
  The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry
  The International FOP Association

See all trials for Fibrodysplasia ossificans progressiva →